Deutsche Bank Aktiengesellschaft Issues Positive Forecast for Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price

Xenon Pharmaceuticals (NASDAQ:XENE) had its price target increased by investment analysts at Deutsche Bank Aktiengesellschaft from $56.00 to $90.00 in a note issued to investors on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Deutsche Bank Aktiengesellschaft’s price objective would suggest a potential upside of 43.40% from the stock’s previous close.

A number of other equities research analysts have also recently commented on the company. Guggenheim reissued a “buy” rating and set a $90.00 price target on shares of Xenon Pharmaceuticals in a report on Monday. Morgan Stanley set a $97.00 price target on Xenon Pharmaceuticals in a research report on Monday. Weiss Ratings reissued a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a research note on Friday, January 9th. Needham & Company LLC upped their price objective on Xenon Pharmaceuticals from $58.00 to $80.00 and gave the company a “buy” rating in a research report on Monday. Finally, Stifel Nicolaus set a $66.00 price target on Xenon Pharmaceuticals in a report on Tuesday, February 10th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Xenon Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $69.59.

Xenon Pharmaceuticals Stock Performance

Shares of Xenon Pharmaceuticals stock opened at $62.76 on Tuesday. The stock has a market capitalization of $5.22 billion, a PE ratio of -14.39 and a beta of 0.91. Xenon Pharmaceuticals has a 52-week low of $26.74 and a 52-week high of $62.91. The company has a 50-day simple moving average of $42.62 and a two-hundred day simple moving average of $41.41.

Xenon Pharmaceuticals (NASDAQ:XENE) last released its quarterly earnings data on Thursday, February 26th. The biopharmaceutical company reported ($1.31) earnings per share for the quarter, missing the consensus estimate of ($1.20) by ($0.11). During the same quarter in the previous year, the firm earned ($0.84) EPS. As a group, equities research analysts forecast that Xenon Pharmaceuticals will post -3.1 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Ian Mortimer sold 40,000 shares of the company’s stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $44.43, for a total transaction of $1,777,200.00. Following the completion of the transaction, the chief executive officer owned 6,000 shares in the company, valued at $266,580. This represents a 86.96% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 4.07% of the company’s stock.

Institutional Trading of Xenon Pharmaceuticals

Several hedge funds have recently made changes to their positions in the company. Goldman Sachs Group Inc. lifted its stake in Xenon Pharmaceuticals by 7.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 442,732 shares of the biopharmaceutical company’s stock worth $14,854,000 after acquiring an additional 32,486 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in Xenon Pharmaceuticals by 73.6% in the second quarter. Bank of New York Mellon Corp now owns 436,020 shares of the biopharmaceutical company’s stock valued at $13,647,000 after buying an additional 184,873 shares during the last quarter. ProShare Advisors LLC purchased a new stake in Xenon Pharmaceuticals during the second quarter worth approximately $577,000. Nan Fung Trinity HK Ltd. purchased a new position in shares of Xenon Pharmaceuticals during the second quarter worth about $4,964,000. Finally, Geode Capital Management LLC lifted its stake in Xenon Pharmaceuticals by 1,294.2% in the second quarter. Geode Capital Management LLC now owns 970,343 shares of the biopharmaceutical company’s stock valued at $30,369,000 after buying an additional 900,746 shares during the last quarter. Hedge funds and other institutional investors own 95.45% of the company’s stock.

Key Xenon Pharmaceuticals News

Here are the key news stories impacting Xenon Pharmaceuticals this week:

• Positive Sentiment: Company-reported positive topline Phase 3 X-TOLE2 results for azetukalner showed a statistically significant reduction in focal-onset seizures, underpinning management’s plan to pursue regulatory filings and expanding commercial opportunity for a differentiated KV7 potassium-channel opener. GlobeNewswire: Positive Topline Data
• Positive Sentiment: Major media and wire services (Reuters, The Globe and Mail and others) highlighted the late‑stage success, increasing visibility and driving buying interest from momentum and fundamental investors. Reuters: Late‑stage trial met main goal
• Neutral Sentiment: Company hosted/discussed topline results in a call/transcript that provides additional trial detail, endpoints and next steps (useful for modelling approval timing, label and addressable market). Seeking Alpha: Transcript of results discussion
• Neutral Sentiment: Trading was temporarily halted prior to the announcement for “news pending,” a routine regulatory/market control that concentrated order flow at the release time and amplified the initial move. (No separate link available.)
• Negative Sentiment: Xenon concurrently announced a proposed underwritten public offering of $500 million (with a 30‑day option for an additional $75 million) of common shares — a potentially dilutive financing that could cap near‑term upside despite the positive clinical news. GlobeNewswire: Proposed public offering
• Negative Sentiment: Some analysts and commentaries caution the post‑data valuation may be rich and note market/commercial risks (crowded antiseizure market, adverse-event profile and execution risk), which could pressure the stock if expectations are not met. Seeking Alpha: Valuation caution

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.